Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of BMS-986310 alone and with nivolumab in advanced solid tumors
MOH_2019-02-28_003726Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ONO-4578 and nivolumab in Non-hematologic malignancy (4 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Safety and tolerability and Dose selection. Started Feb 2019; status: completed.
02
Drugs
ONO-4578nivolumab
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on MOH_2019-02-28_003726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-02-28_003726.